'Cysteine' Chapel, Holy Grail? Principia Funding Nets $12.5M
By Randy Osborne
Tuesday, October 30, 2012
Principia Biopharma Inc.'s $12.5 million in new money should get the company's lead compound into human trials, but the company is entertaining the idea of partners to advance other prospects arising from its platform that develops reversible, tightly binding covalent therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.